Hansa Biopharma Interim Report January-September 2023 (2) (Información remitida por la empresa firmante) Last, I want to highlight that Hansa Biopharma AB was recently certified as a Great Place to Work for the fourth consecutive year.
New data from LEQEMBI (lecanemab-irmb) phase 3 Clarity AD study and subcutaneous formulation presented at CTAD (2)
New data from LEQEMBI (lecanemab-irmb) phase 3 Clarity AD study and subcutaneous formulation presented at CTAD (1)
